MoonLake Immunotherapeutics (MLTX) reported a Q3 net loss Thursday of $0.56 per diluted share, widening from a loss of $0.18 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.43.

The clinical-stage biopharmaceutical company did not report any revenue for the quarter ended Sept. 30.

MoonLake said it had $493.9 million in cash, cash equivalents, and short-term marketable debt securities as of Sept. 30.